Loading...

Intra-Cellular Therapies, Inc.

ITCINASDAQ
HealthcareDrug Manufacturers - Specialty & Generic
$131.87
$0.00(0.00%)

Intra-Cellular Therapies, Inc. ITCI Peers

See (ITCI) competitors and their performances in Stock Market.

Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
ITCI$131.87N/A14B-180.64-$0.73N/A
ZTS$170.01+0.83%75.7B30.52$5.57+1.10%
HLN$11.07-0.49%50B25.73$0.43+1.52%
TAK$14.96-0.23%47.1B65.02$0.23+3.94%
TEVA$17.77+3.01%20.4B-15.45-$1.15N/A
RDY$15.54+0.07%12.9B19.67$0.79+0.62%
NBIX$125.34+0.59%12.4B42.49$2.95N/A
CTLT$63.48N/A11.5B-27.84-$2.28N/A
VTRS$8.71+2.96%10.2B-2.74-$3.18+5.53%
RGC$695.00+11.21%9B-2171.87-$0.32N/A
Showing 1 to 10 of 100 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

ITCI vs ZTS Comparison

ITCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ITCI stands at 14B. In comparison, ZTS has a market cap of 75.7B. Regarding current trading prices, ITCI is priced at $131.87, while ZTS trades at $170.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ITCI currently has a P/E ratio of -180.64, whereas ZTS's P/E ratio is 30.52. In terms of profitability, ITCI's ROE is -0.07%, compared to ZTS's ROE of +0.51%. Regarding short-term risk, ITCI is less volatile compared to ZTS. This indicates potentially lower risk in terms of short-term price fluctuations for ITCI.

Stock Price Comparison

Loading...

Frequently Asked Questions